Search

Author/Creator Terai, Masaru

1. 307. EFFICACY OF PRIMARY TREATMENT WITH IMMUNOGLOBULIN PLUS CYCLOSPORINE FOR PREVENTION OF CORONARY ARTERY ABNORMALITIES IN KAWASAKI DISEASE PATIENTS PREDICTED TO BE AT INCREASED RISK OF IVIG NON- RESPONSE (KAICA STUDY): A CONTROLLED, PHASE 3, RANDOMISED, OPEN-LABEL, BLINDED-ENDPOINTS TRIAL. (29th March 2019)

Authors:
Hamada, Hiromichi; Suzuki, Hiroyuki; Onouchi, Yoshihiro; Ebata, Ryota; Terai, Masaru; Fuse, Shigeto; Okajima, Yoshitomo; Kurotobi, Shunji; Hirai, Katsuki; Soga, Takashi; Ishiguchi, Yukiko; Okuma, Yoshiaki; Takada, Nobuyuki; Yanai, Masaaki; Sato, Junichi; Nakayashiro, Mami; Ayusawa, Mamoru; Yamamo...
Journal:
Rheumatology
Issue:
Volume 58(2019)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Comprehensive pathogen detection associated with four recurrent episodes of Kawasaki disease in a patient during a single year using next-generation sequencing. Issue 1 (1st February 2016)

Authors:
Hamada, Hiromichi; Sekizuka, Tsuyoshi; Oba, Kunihiro; Katano, Harutaka; Kinumaki, Akiko; Terai, Masaru; Mizutani, Tetsuya; Kuroda, Makoto
Journal:
JMM case reports
Issue:
Volume 3:Issue 1(2016)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Comprehensive pathogen detection associated with four recurrent episodes of Kawasaki disease in a patient during a single year using next-generation sequencing. Issue 2 (1st February 2016)

Authors:
Hamada, Hiromichi; Sekizuka, Tsuyoshi; Oba, Kunihiro; Katano, Harutaka; Kinumaki, Akiko; Terai, Masaru; Mizutani, Tetsuya; Kuroda, Makoto
Journal:
JMM case reports
Issue:
Volume 3:Issue 2(2016)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Issue 10176 (16th March 2019)

Authors:
Hamada, Hiromichi; Suzuki, Hiroyuki; Onouchi, Yoshihiro; Ebata, Ryota; Terai, Masaru; Fuse, Shigeto; Okajima, Yoshitomo; Kurotobi, Shunji; Hirai, Katsuki; Soga, Takashi; Ishiguchi, Yukiko; Okuma, Yoshiaki; Takada, Nobuyuki; Yanai, Masaaki; Sato, Junichi; Nakayashiro, Mami; Ayusawa, Mamoru; Yamamo...
Journal:
Lancet
Issue:
Volume 393:Issue 10176(2019)
Page Start:
1128
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial). Issue 12 (1st December 2015)

Authors:
Aoyagi, Reiko; Hamada, Hiromichi; Sato, Yasunori; Suzuki, Hiroyuki; Onouchi, Yoshihiro; Ebata, Ryota; Nagashima, Kengo; Terauchi, Moe; Terai, Masaru; Hanaoka, Hideki; Hata, Akira
Other Names:
author non-byline.; Hirai Katsuki author non-byline.; Yanai Masaaki author non-byline.; Masuda Hiroshi author non-byline.; Kamada Masahiro author non-byline.; Higaki Takashi author non-byline.; Nakayashiro Mami author non-byline.; Sato Junichi author non-byline.; Suwabe Shinichi author non-bylin...
Journal:
BMJ open
Issue:
Volume 5:Issue 12(2015)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗